Rare Disease · United Kingdom · In-Market

UK Myasthenia Gravis Competitive Intelligence

No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid.

7,000–10,000 UK patients3 approved agentsIn-MarketUpdated Q3 2026
Commission This Brief View Sample Brief
Market United States GCC (Gulf) United Kingdom Stage
The Landscape

The largest NICE access gap in this rare-disease set: no novel agent is yet NHS-commissioned for generalised myasthenia gravis.

An estimated 7,000–10,000 UK patients have generalised myasthenia gravis, with roughly 4,000 having moderate-to-severe disease eligible for novel agents. Eculizumab's (Soliris, AstraZeneca) UK myasthenia gravis appraisal, TA636, was terminated by NICE in June 2020 after the manufacturer withdrew without submitting cost-effectiveness evidence, leaving refractory gMG patients dependent on Individual Funding Request exceptional-case access only. No cost-per-QALY figure was ever published: this was a manufacturer decision not to pursue UK reimbursement, not a rejection on value grounds. This remains the widest NICE access gap among the UK rare-disease markets in this set: no novel biologic is currently NHS-commissioned for generalised myasthenia gravis.

NICE rejected efgartigimod alfa (Vyvgart/Vyvgart Hytrulo, argenx) for generalised myasthenia gravis in its June 2025 final guidance (TA1069, appraisal GID-TA10986), the first FcRn-antagonist verdict in the class. UK neurology centres continue to access efgartigimod for severe refractory patients via Named Patient Programme, with an estimated 200 UK patients reached this way despite the negative TA. Rozanolixizumab (Rystiggo, UCB) is now the FcRn-antagonist class's one remaining live NICE bid: a positive recommendation with an agreed PAS would be the first transformative access event for the class in the UK, opening NHS commissioning at an estimated 25 specialist neuromuscular centres and putting UCB ahead of argenx on NHS access despite trailing on approval.

7,000–10,000
estimated UK generalised myasthenia gravis patients; ~4,000 with moderate-severe disease eligible for novel agents
TA636
NICE's eculizumab MG appraisal, terminated in 2020 after the manufacturer withdrew before a cost-effectiveness verdict was reached
~200
UK gMG patients accessing efgartigimod via Named Patient Programme, despite NICE's June 2025 rejection (TA1069)
DRUG LANDSCAPE

UK Myasthenia Gravis agents by NICE access stage — 2026

Drug (Brand / INN)MechanismCompanyUK Regulatory / NICE StatusKey Trial ResultNHS Access Status
Soliris (eculizumab)C5 complement inhibitor IV — refractory AChR+ gMGAstraZenecaMHRA approved for MG; NICE appraisal (TA636) terminated in 2020 — manufacturer withdrew before assessmentREGAIN trial evidence base; no NICE cost-effectiveness verdict was ever reachedVery limited NHS access; IFR pathway only; estimated <50 UK gMG patients
Vyvgart / Vyvgart Hytrulo (efgartigimod alfa)FcRn antagonist IV/SCargenxEMA approved; MHRA 2022; NICE did not recommend (TA1069, June 2025)ADAPT trial; NICE did not recommend based on the submitted evidenceNamed Patient Programme access at specialist centres; ~200 UK patients reached despite the 2025 NICE rejection
Rystiggo (rozanolixizumab)FcRn antagonist SCUCBEMA approved; MHRA 2023; NICE appraisal not yet initiatedMycarinG trial; EMA-approved for generalised MGLimited Named Patient Programme access; NICE appraisal pending, following efgartigimod's 2025 TA1069 rejection

Sources: MHRA and EMA regulatory filings; REGAIN trial (eculizumab); ADAPT trial (efgartigimod, NEJM); MycarinG trial (rozanolixizumab); NICE TA636 (eculizumab, terminated appraisal, 2020); NICE TA1069 (efgartigimod, appraisal GID-TA10986, June 2025); Myasthenia Gravis Association UK 2023 report.

Commercial Questions

What this brief answers

Every section answers a named commercial question your team is asking, scoped to your asset.

01
What cost-effectiveness evidence and PAS structure would let rozanolixizumab succeed where NICE rejected efgartigimod (TA1069, 2025) and eculizumab's appraisal was withdrawn before a verdict (TA636, 2020)?

Delivers

  • NICE's efgartigimod rejection rationale (TA1069, June 2025)
  • why eculizumab's appraisal (TA636) never reached a cost-effectiveness verdict
  • the PAS discount level rozanolixizumab would need
  • MycarinG trial evidence positioning versus ADAPT and REGAIN
02
How is argenx sustaining ~200-patient Named Patient Programme access for efgartigimod despite NICE's 2025 rejection (TA1069), and what does that signal for rozanolixizumab's pending appraisal?

Delivers

  • NPP access criteria at UK neuromuscular centres post-rejection
  • ~200-patient current reach
  • the read-through risk for UCB's still-pending rozanolixizumab appraisal
03
Which of the ~25 UK specialist neuromuscular centres would be first to commission rozanolixizumab on a positive NICE decision, and what does the Myasthenia Gravis Association UK's advocacy position signal about access pressure after two consecutive NICE setbacks for the class?

Delivers

  • Centre-level commissioning readiness
  • patient advocacy dynamics
  • the practical timeline from a positive TA to first NHS prescription

Custom brief delivered in 72 hours.

Commission This Brief
Contents

What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

1 Market Map & the NICE Access Gap 4 pp
  • [object Object]
  • [object Object]
2 Competitive Drug Profiles (3 agents) 7 pp
  • [object Object]
  • [object Object]
3 Eculizumab's Terminated NICE Appraisal (TA636) — Precedent Analysis 3 pp
  • [object Object]
  • [object Object]
4 Efgartigimod's NICE Rejection (TA1069) & the Rozanolixizumab PAS Scenario 4 pp
  • [object Object]
  • [object Object]
5 Named Patient Programme Access & Advocacy Pressure 3 pp
  • [object Object]
  • [object Object]
6 KOL Network & Neuromuscular Centre Readiness 3 pp
  • [object Object]
  • [object Object]
Appendix and source ledger included · 45-minute analyst readout included with delivery
Formats

Included with every brief

PDF
PDF Brief
Myasthenia Gravis CI Brief — Complete Edition
20-25 page analyst brief: competitive drug profiles, the NICE access gap analysis, the efgartigimod NICE appraisal, and Named Patient Programme dynamics.
XLS
Excel Model
Drug Comparison & NICE Appraisal Grid
Drug comparison table, NICE appraisal status grid, and access-pathway data in editable Excel format.
PPT
PowerPoint
Executive Readout — PowerPoint
12-15 slide readout deck for commercial team presentations, formatted to AXLRx design standards.
Methodology

How AXLRx builds this brief

Prepared by MoatRx analysts.

Every AXLRx brief is built from primary regulatory sources (MHRA, EMA, NICE), peer-reviewed literature, and patient-advocacy reporting — not secondary summaries. Findings are independently verified before inclusion.

Myasthenia Gravis UK CI sources: NICE TA636 (eculizumab, terminated appraisal, 2020), NICE TA1069 (efgartigimod, appraisal GID-TA10986, published June 2025), REGAIN, ADAPT and MycarinG primary trial data, Muscle Study Group UK MG prevalence data (2022), and Myasthenia Gravis Association UK reporting (2023).

  • MHRA and EMA approval status verified against current regulatory filing information
  • NICE eculizumab appraisal status verified against the published TA636 termination notice (2020)
  • Clinical trial evidence verified against REGAIN, ADAPT and MycarinG primary trial data
  • NICE efgartigimod appraisal outcome verified against the published TA1069 final guidance (June 2025)
FAQ

Frequently asked questions

Deliverables
What formats are included with every brief?
Every commissioned brief includes three deliverables: a 20–30 page PDF analyst brief with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources
What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only — regulatory databases (FDA, MHRA, SFDA), peer-reviewed journals (NEJM, Blood, JAMA), live payer coverage policy documents, and HTA body publications (NICE, ICER, MOH). No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered brief.
Customisation
Can I tailor the brief to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional payer markets, pipeline agent profiles, or country-specific deep-dives) can be added to any standard brief. Commission via the intake form to start.
Get Started

Commission this brief

AXLRx delivers Myasthenia Gravis competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams targeting the UK NHS pathway. Custom brief in 72 hours.

1
Submit your request

Use the intake form to specify your indication, geography, and commercial question.

2
Scoping call

AXLRx analyst confirms scope, comparators, and delivery format.

3
Delivery

Research-verified brief in 72 hours with optional analyst readout.

Request Brief View sample briefs